SERB Pharmaceuticals in the news
global supplier rare medicines
Tamtam found 17 recent articles about SERB Pharmaceuticals.
- SERB Applauds Publication of Consensus Statements and Recommendations for Neuroblastoma Care in Pediatric Blood & Cancer
SERB Pharmaceuticals supported the publication of 30 consensus statements to improve neuroblastoma care for patients and caregivers in Pediatric Blood & Cancer.
- Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
Hansa Biopharma completed a €115 million licensing agreement with SERB Pharmaceuticals for the commercialization of Idefirix in Europe and MENA.
- SERB Sizes Up €1bn Sales With M&A Savoir Faire
SERB Pharmaceuticals targets €1bn in sales, leveraging its M&A expertise.
- Hansa licenses Idefirix to SERB for $133m
SERB Pharmaceuticals is paying $133.5 million to license and commercialize a specialized kidney transplant treatment across Europe and the Middle East.
- Mayer Brown advises SERB Pharmaceuticals on the agreement entered into with Hansa Biopharma AB to acquire European and MENA rights to Idefirix®(imlifidase)
SERB Pharmaceuticals is acquiring the exclusive rights to the kidney transplant drug Idefirix® across Europe, the UK, and the MENA region.
- Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115 million deal
Hansa Biopharma licensed its kidney transplant drug IDEFIRIX to SERB Pharmaceuticals in a €115 million deal covering Europe and the Middle East.
- Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
Hansa Biopharma signed a €115 million deal with SERB Pharmaceuticals to commercialize its kidney transplant treatment across Europe and the Middle East.
- SERB signs agreement to acquire Idefirix rights for $133.6m
Acquisition of regional rights for the kidney transplant drug Idefirix from Hansa Biopharma for $133.6 million.
- SERB Pharmaceuticals buys European and MENA rights to kidney transplant drug Idefirix for €115M
SERB Pharmaceuticals acquired the European and MENA rights to the kidney transplant drug Idefirix from Hansa Biopharma for €115 million.
- SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
SERB Pharmaceuticals is acquiring the rights to kidney transplant drug Idefirix in Europe and the MENA region for 115 million euros.
- Hansa Biopharma Signs €115 Million Imlifidase Licensing Agreement with SERB
SERB Pharmaceuticals has secured exclusive rights to develop and commercialize the transplant desensitization therapy imlifidase in Europe and MENA for €115 million.
- SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug
SERB is acquiring the commercial rights for Idefirix in Europe and MENA from Hansa Biopharma for an upfront payment of €110 million.
- SERB Pharma to acquire European and MENA rights to Idefirix from Hansa
SERB Pharmaceuticals will acquire exclusive rights from Hansa Biopharma to develop and commercialize Idefirix in Europe and MENA regions.
- SERB Pharmaceuticals Announces ThyroSafe 130 mg Potassium Iodide Tablets are Now Commercially Available in the US
SERB Pharmaceuticals is launching FDA-approved ThyroSafe 130 mg tablets in the US market to provide thyroid protection during nuclear radiation emergencies.
- Dr Vignesh Rajah
Dr. Vignesh Rajah, an experienced medical and clinical leader, has been appointed as the new Chief Medical Officer at SERB Pharmaceuticals to advance patient care and expand scientific capabilities.
- SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for $412 Million
SERB Pharmaceuticals is acquiring oncology-focused Y-mAbs Therapeutics for $412 million to expand its rare disease and pediatric cancer treatment portfolio.
- Y-Mabs falls to Serb | ApexOnco - Clinical Trials news and analysis
SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics to expand its specialty and rare disease portfolio with an approved neuroblastoma treatment.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like SERB Pharmaceuticals?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies